These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24077403)

  • 1. Melanoma mutagenesis and aberrant cell signaling.
    Bello DM; Ariyan CE; Carvajal RD
    Cancer Control; 2013 Oct; 20(4):261-81. PubMed ID: 24077403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment implications of the emerging molecular classification system for melanoma.
    Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
    Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular pathology of cutaneous melanoma.
    Bogenrieder T; Herlyn M
    Cancer Biomark; 2010; 9(1-6):267-86. PubMed ID: 22112480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
    Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
    Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.
    Yilmaz I; Gamsizkan M; Kucukodaci Z; Berber U; Demirel D; Haholu A; Narli G
    Indian J Pathol Microbiol; 2015; 58(3):279-84. PubMed ID: 26275246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic activation of KIT in distinct subtypes of melanoma.
    Curtin JA; Busam K; Pinkel D; Bastian BC
    J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
    Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
    J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
    Yazdi AS; Ghoreschi K; Sander CA; Röcken M
    Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
    Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
    J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Markers and Targets in Melanoma.
    Teixido C; Castillo P; Martinez-Vila C; Arance A; Alos L
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571969
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras, Raf, and MAP kinase in melanoma.
    Solus JF; Kraft S
    Adv Anat Pathol; 2013 Jul; 20(4):217-26. PubMed ID: 23752084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Genomic Profiling of Acral Melanoma.
    Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
    J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
    Hutchinson KE; Johnson DB; Johnson AS; Sanchez V; Kuba M; Lu P; Chen X; Kelley MC; Wang Q; Zhao Z; Kris M; Berger MF; Sosman JA; Pao W
    Oncotarget; 2015 Sep; 6(26):22348-60. PubMed ID: 26084293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report.
    Patel SP; Kim DW; Lacey CL; Hwu P
    Medicine (Baltimore); 2016 Jan; 95(4):e2336. PubMed ID: 26825879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.